Is AICAR Legal? FDA Status and Regulations Explained (2026)
Key Takeaways
- AICAR is not FDA-approved for any clinical indication in the United States as of March 2026. Its regulatory classification is "research use only."
- No licensed compounding pharmacy can legally dispense AICAR to patients under 503A or 503B frameworks, because it lacks an FDA-approved drug counterpart and has not been nominated to — or placed on — the FDA's bulk drug substances list for compounding.
- AICAR is not a DEA-scheduled controlled substance, but that does not make it legal to sell or prescribe for human use. Non-scheduled ≠ legal.
- Products sold online as "research use only" AICAR occupy a legal grey zone that carries real risk for buyers. Customs seizure is possible, and sellers of unapproved drugs marketed for human use can face FDA enforcement action.
- The FDA has taken enforcement action against companies marketing unapproved peptide and research compound products for human use. Patients and providers should consult FDA.gov for current enforcement activity.
- If you're looking for legal, clinically supported options for metabolic health, there are FDA-approved and legally compoundable alternatives worth discussing with your provider.
Regulatory Status at a Glance
| Category | Status | Detail |
|---|---|---|
| FDA Approval | ❌ Not Approved | No approved NDA, BLA, or IND for human therapeutic use |
| FDA Classification | Research Use Only | Not authorized for clinical or consumer use |
| Compounding (503A/503B) | ❌ Not Eligible | Not on FDA bulk drug substances list; cannot be legally compounded |
| DEA Scheduling | Not Scheduled | Not a controlled substance under the Controlled Substances Act |
| Prescription Availability | ❌ Not Available | Cannot be legally prescribed as a therapeutic agent in the US |
| OTC Availability | ❌ Not Legal for Human Use | Domestic sale for human consumption is not authorized |
| Research Use | ✅ Permitted (with conditions) | Available to qualified researchers through licensed chemical suppliers |
| International (EU/UK/AUS/CA) | Not Approved | No regulatory approval for human use in major jurisdictions |
Current FDA Status
AICAR — formally known as 5-aminoimidazole-4-carboxamide ribonucleotide, with the CAS number 2627-69-2 — is not FDA-approved for any human therapeutic indication.[1] There is no New Drug Application (NDA), Biologics License Application (BLA), or approved Investigational New Drug (IND) pathway that permits its clinical use in patients in the United States. Its FDA classification is unambiguous: research use only.
What does "research use only" mean from a regulatory standpoint? Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a substance intended to diagnose, cure, treat, mitigate, or prevent a disease in humans is a drug. If that drug hasn't gone through FDA's approval process — meaning it hasn't demonstrated safety and efficacy through clinical trials — it cannot legally be marketed, sold, or distributed for human use in the US.[2] AICAR falls squarely into this category.
The compound has been studied extensively in preclinical settings. It's a cell-permeable AMP analog that activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis.[3] That mechanism is genuinely interesting — AMPK activation influences mitochondrial biogenesis, fatty acid oxidation, and glucose uptake, which is why researchers have explored AICAR in the context of metabolic disease, exercise physiology, and even anti-aging biology. But interesting preclinical data is not the same as FDA approval. The compound has not completed the Phase II and Phase III human clinical trial process required to establish safety and efficacy in a defined patient population.
No FDA-approved drug contains AICAR as its active ingredient, which also means there's no reference listed drug from which a compounding pharmacy could derive authorization. That distinction matters enormously for the compounding analysis below.
Compounding Status
The short answer: no licensed compounding pharmacy can legally prepare AICAR for patient use under current FDA rules.
Here's why that matters. Under Section 503A of the FD&C Act, traditional compounding pharmacies can prepare customized medications for individual patients — but only under specific conditions.[2] One critical condition is that the drug being compounded must either be an FDA-approved drug (or a component of one), or it must appear on the FDA's list of bulk drug substances that can be used in compounding (sometimes called the "503A bulk list" or the "Category 1" list). AICAR is on neither list.
The 503B outsourcing facility framework — which governs larger-scale compounding operations — has similar constraints. Outsourcing facilities can compound drugs from bulk substances, but only those the FDA has specifically evaluated and determined are appropriate for compounding.[2] AICAR has not been nominated to, reviewed for, or placed on any FDA bulk drug substances list that would authorize its compounding under 503B.
This is meaningfully different from peptides like BPC-157 or TB-500, which have also faced compounding restrictions but have at least been nominated for FDA review. AICAR doesn't have that status. If a compounding pharmacy is offering AICAR to patients, they are operating outside the legal framework — full stop.
The FDA has been increasingly active in scrutinizing compounding pharmacies that prepare unapproved substances. Providers who order from such pharmacies, and patients who receive such preparations, may not face direct criminal liability in most cases, but the supply chain itself is operating illegally. That's a risk worth understanding before you accept a prescription for a compounded peptide you can't verify.
Enforcement Actions
The FDA has taken enforcement action against companies marketing unapproved AICAR products and other research compounds for human use. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.[1]
What the enforcement pattern generally looks like for unapproved research compounds: the FDA's primary tool is the warning letter, typically issued when a company's website or marketing materials make claims that the product is intended for human use — even if the label technically says "not for human consumption." Courts and regulators have consistently held that "research use only" labeling doesn't immunize a seller if the product is clearly being marketed for human therapeutic use.[2]
The FDA also works with US Customs and Border Protection to intercept shipments of unapproved drugs entering the country. If you order AICAR from an overseas supplier, there's a real possibility your package gets flagged and seized at the border. You likely won't face criminal charges for a small personal-use quantity, but you'll lose your money and your product.
For sellers, the stakes are higher. Marketing an unapproved drug for human use can trigger FDA warning letters, injunctions, and in serious cases, criminal referrals to the Department of Justice. The agency has pursued enforcement against peptide and research compound vendors who make therapeutic claims — and AICAR's profile as a purported "exercise mimetic" and metabolic enhancer makes it exactly the kind of product that draws regulatory attention.
Prescription vs. Over-the-Counter vs. Research Use
Let's be direct about each pathway, because there's a lot of confusion online.
Prescription: You cannot get a legal prescription for AICAR in the United States. Prescribing authority only exists for FDA-approved drugs (or drugs in approved clinical trials). Since AICAR has neither, no licensed physician can write a legal prescription for it as a therapeutic agent. A provider who does is prescribing an unapproved drug — which is a different legal situation than off-label prescribing (more on that below).
Over-the-counter: There is no legal OTC pathway for AICAR. It's not a dietary supplement — it doesn't qualify under DSHEA (the Dietary Supplement Health and Education Act of 1994) because it's a synthetic research compound, not a vitamin, mineral, herb, or other supplement ingredient with a history of use.[4] Any product sold in a retail context claiming to contain AICAR for human consumption is operating outside the law.
Research use: This is the one legal pathway, and it comes with strict conditions. Qualified researchers — typically at accredited institutions, with appropriate oversight (IRB approval, institutional biosafety protocols) — can purchase AICAR from licensed chemical suppliers for legitimate laboratory research. The product must be labeled "for research use only, not for human use," and it must actually be used that way. A researcher who buys AICAR through a scientific supplier and then self-administers it has stepped outside the legal framework of research use.
The "research use only" label you see on many online vendor sites is not a legal shield for buyers who intend to use the compound themselves. Courts have found that intended use — not labeling — determines whether a product is being sold as a drug. If a vendor's website discusses dosing protocols, injection techniques, and human health benefits alongside a "research use only" disclaimer, that disclaimer doesn't hold up legally.
What "Off-Label" Actually Means
This distinction is critical, and it's one that even some clinicians get wrong.
Off-label prescribing refers to a physician prescribing an FDA-approved drug for an indication, population, or dosage that the FDA hasn't specifically approved. It's legal. It's common — estimates suggest that 20% or more of all prescriptions in the US are written off-label.[4] Oncologists do it constantly. Psychiatrists do it constantly. It's a legitimate medical practice.
But off-label prescribing only applies to drugs that have already cleared the FDA approval process. If a drug has never been approved for anything, prescribing it isn't "off-label" — it's prescribing an unapproved drug. That's a fundamentally different legal and regulatory situation.
AICAR has never been FDA-approved for any indication. So a provider who prescribes it isn't exercising off-label discretion — they're prescribing an unapproved drug, which the FD&C Act generally prohibits. From a malpractice standpoint, this matters: a physician who prescribes an unapproved compound can't fall back on "standard of care" arguments the way they might with an off-label use of an approved drug. The liability exposure is meaningfully higher.
If a clinic or telehealth provider tells you they can prescribe AICAR "off-label," ask them to clarify what FDA approval they're relying on. If they can't name a specific approved indication and NDA number, that's a red flag.
State-Level Variations
Federal law sets the floor here, and states can't override FDA's classification of AICAR as an unapproved drug. But state-level rules still matter in a few ways.
State pharmacy boards have authority over compounding pharmacies operating within their borders. Some state boards have issued specific guidance on peptides and research compounds, and enforcement intensity varies. That said, no state pharmacy board can authorize a compounding pharmacy to dispense AICAR for patient use in a way that overrides federal FDA rules.
Medical licensing boards in some states have taken action against physicians who prescribe unapproved compounds without adequate clinical justification. If you're working with a provider who's offering AICAR as part of a treatment protocol, understand that their license is on the line in a way that's independent of federal enforcement.
Telemedicine rules affect access to peptide therapies broadly. Several states have tightened telemedicine prescribing standards post-COVID, requiring in-person evaluations before prescribing certain compounds. Since AICAR can't be legally prescribed at all, telemedicine rules are somewhat beside the point — but they're worth understanding if you're exploring the broader peptide therapy landscape through telehealth.
States with historically more active pharmaceutical enforcement — California, New York, and Texas among them — tend to see more state-level action against vendors of unapproved compounds. But again: federal law applies nationwide.
International Status
AICAR's legal status outside the US follows a similar pattern: no major regulatory body has approved it for human therapeutic use.
European Union / EMA: The European Medicines Agency has not granted marketing authorization for any AICAR-containing drug product. It is not on the EU's list of authorized medicinal products. Research use is permitted under institutional frameworks, but clinical use is not authorized.[1]
United Kingdom / MHRA: The UK Medicines and Healthcare products Regulatory Agency has not approved AICAR. Post-Brexit, the UK maintains its own regulatory framework, and AICAR has no marketing authorization under it. The MHRA has been active in warning against unlicensed medicines sold online.
Australia / TGA: The Therapeutic Goods Administration classifies unapproved therapeutic goods under a strict framework. AICAR is not included in the Australian Register of Therapeutic Goods (ARTG). Importing it for personal use without a Special Access Scheme authorization is not permitted.[1]
Canada / Health Canada: Health Canada has not authorized AICAR as a drug product. It would be classified as an unapproved drug under the Food and Drugs Act. Health Canada has issued advisories about purchasing unapproved health products online.
One notable international context: AICAR has appeared on the World Anti-Doping Agency (WADA) prohibited list as a metabolic modulator under Section S4.[3] It's been prohibited in sport since 2009. If you're a competitive athlete subject to WADA testing — or testing under any anti-doping authority — AICAR is a banned substance, and this is independent of its pharmaceutical legal status.
